Long-Term Outcomes of Laparoscopic Roux-en-Y Gastric Bypass vs Laparoscopic Sleeve Gastrectomy for Obesity
JAMA Surgery · 01.04.2025 · 160 (4) · 369
DOI: 10.1001/jamasurg.2024.7052 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Surgery, erschienen am 01.04.2025. Verfasst von Marko Kraljevic und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clarunis, Department of Visceral Surgery, University Digestive Health Care Center, St Clara Hospital and University Hospital, Basel, Switzerland. Hauptthemen laut MEDLINE: Gastrectomy, Gastric Bypass, Laparoscopy, Obesity, Morbid. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Reports on long-term outcomes from randomized clinical trials comparing laparoscopic sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) are scarce.
Objective
To compare long-term weight and metabolic outcomes, reoperation rates, and quality of life for patients undergoing SG vs RYGB at 10 years and beyond. Design, Setting, and Participants The SM-BOSS (Swiss Multicenter Bypass or Sleeve Study) randomized clinical trial was conducted from January 2007 to November 2011 at 4 bariatric centers in Switzerland. (The last follow-up was obtained in July 2023.) A total of 3971 patients with severe obesity were assessed, and 217 patients were enrolled and randomized to undergo SG or RYGB.
Interventions
Laparoscopic SG or RYGB. Main Outcomes and Measures The primary outcome of the SM-BOSS trial was the percentage excess body mass index loss (%EBMIL) at 5 years. The present study reports on the long-term weight and metabolic outcomes at 10 years and beyond, including changes in weight and obesity-related diseases, reoperation rates, and quality of life.
Results
Of 217 patients randomized to undergo SG or RYGB, mean (SD) age was 42.5 (11.1) years, mean (SD) baseline BMI was 43.9 (5.3), and 156 patients (71.9%) were female. Of 217 patients, 110 patients were randomized to RYGB and 107 to SG. Complete 10-year follow-up is available for 65.4% of patients. In the intention-to-treat population, mean (SD) %EBMIL was 60.6% (25.9) after SG and 65.2% (26.0) after RYGB ( P = .29). Patients who underwent SG had significantly higher conversion rates because of insufficient weight reduction or reflux compared to RYGB (29.9% vs 5.5%; P < .001). Patients undergoing RYGB had significantly higher mean (SD) %EBMIL compared to SG after 10 years in the per-protocol (PP) population (65.9% [26.3] vs 56.1% [25.2]; P = .048). However, mean (SD) percentage total weight loss was not significantly different between groups (RYGB: 27.7% [10.8]; SG: 25.5% [15.1]; P = .37). SG patients had significantly more de novo gastroesophageal reflux (GERD) compared with RYGB ( P = .02). Conclusions and Relevance In the SM-BOSS randomized clinical trial, RYGB led to significantly higher %EBMIL in the PP population compared with SG beyond 10 years of follow-up, with better results for GERD. Patients undergoing SG experienced a significantly higher number of conversions to different anatomy compared with RYGB. Trial Registration ClinicalTrials.gov Identifier NCT00356213
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Clarunis, Department of Visceral Surgery, University Digestive Health Care Center, St Clara Hospital and University Hospital, Basel, Switzerland.
- Metabolic Research, St Clara Research, St Clara Hospital, Basel, Switzerland.
- Department of Clinical Research, Medical Faculty of the University of Basel, Basel, Switzerland.
- Department of Internal Medicine and Endocrinology, St Clara Hospital, Basel, Switzerland.
- Department of Visceral Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland.
- Metabolic Center St Gallen, friendlyDocs, St Gallen, Switzerland.
Zitieren
APA
Kraljevic, M., Süsstrunk, J., Wölnerhanssen, B. K., Peters, T., Bueter, M., Gero, D., Schultes, B., Poljo, A., Schneider, R., & Peterli, R. (2025). Long-Term Outcomes of Laparoscopic Roux-en-Y Gastric Bypass vs Laparoscopic Sleeve Gastrectomy for Obesity. JAMA Surgery, 160(4), 369. https://doi.org/10.1001/jamasurg.2024.7052
Vancouver
Kraljevic M, Süsstrunk J, Wölnerhanssen BK, Peters T, Bueter M, Gero D, et al. Long-Term Outcomes of Laparoscopic Roux-en-Y Gastric Bypass vs Laparoscopic Sleeve Gastrectomy for Obesity. JAMA Surgery. 2025;160(4):369. doi:10.1001/jamasurg.2024.7052
BibTeX
@article{Kraljevic2025,
author = {Kraljevic, Marko and Süsstrunk, Julian and Wölnerhanssen, Bettina Karin and Peters, Thomas and Bueter, Marco and Gero, Daniel and Schultes, Bernd and Poljo, Adisa and Schneider, Romano and Peterli, Ralph},
title = {Long-Term Outcomes of Laparoscopic Roux-en-Y Gastric Bypass vs Laparoscopic Sleeve Gastrectomy for Obesity},
journal = {JAMA Surgery},
year = {2025},
volume = {160},
number = {4},
pages = {369},
doi = {10.1001/jamasurg.2024.7052}
}
EUVIMED